Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by C. Flohr
A national audit of oral propranolol for the treatment of Infantile Hemangiomas
RESEARCH LETTER C. Cotter, Corresponding Author cottercl@tcd.ie orcid.org/0000-0002-4272-6534 Department of Paediatric Dermatology, St John’s Institute of Dermatology, Guy’s & St Thomas’ NHS Foundation Trust, UK Correspondence: C. Cotter Email: cottercl@tcd.ie Contribution: Formal analysis (equal), Writing - original draft (equal) Search for more papers by this author L.
New international reporting guidelines for clinical trials evaluating effectiveness of artificial intelligence interventions in dermatology: strengthening the SPIRIT of robust trial reporting
Editorial PDF ShareShare Artificial intelligence (AI) can be defined simply as the ability of computers to simulate intelligent human behaviour. Machine learning is a branch of AI that uses algorithms and statistical models that are able to learn from data. Deep learning is a specific form of machine learning. AI can refer to either machine learning or deep learning.1 The potential for AI and machine learning to improve the management of skin diseases is immense.
Putting the burden of skin diseases on the global map
Editorial PDF ShareShare Skin diseases are the fourth most common cause of all human disease, affecting almost one‐third of the world’s population, yet their burden is often underestimated, despite their visibility.1, 2 Burden of disease is a concept that was first developed in the 1990s by the Harvard School of Public Health, the World Bank and the World Health Organization (WHO) to describe death and loss of health due to diseases, injuries and risk factors for all regions of the world.
All aboard the BJD for global dissemination of high‐quality dermatology clinical practice guidelines
Email or Customer ID Please check your email for instructions on resetting your password. If you do not receive an email within 10 minutes, your email address may not be registered, and you may need to create a new Wiley Online Library account.
Publication of national dermatology guidelines as a Research Letter in the BJD: can less ever be enough?
Editorial E.J. van Zuuren Corresponding Author E-mail address: E.J.van_Zuuren@lumc.nl https://orcid.org/0000-0002-4780-0182 Department of Dermatology, Leiden University Medical Centre, Leiden, the Netherlands Search for more papers by this author Get access to the full version of this article. View access options below. If you have previously obtained access with your personal account, Please log in.
Common methodological pitfalls and new developments in systematic review meta‐analyses
Email or Customer ID "Please check your email for instructions on resetting your password. If you do not receive an email within 10 minutes, your email address may not be registered, and you may need to create a new Wiley Online Library account.
Why does the BJD require registration of systematic reviews and meta‐analyses?
Editorial Why does the BJD require registration of systematic reviews and meta‐analyses? K. Abuabara Corresponding Author E-mail address: katrina.abuabara@ucsf.edu http://orcid.org/0000-0002-7736-6946 Program for Clinical Research, Department of Dermatology, University of California San Francisco (UCSF), San Francisco, CA, U.S.A. Search for more papers by this author Conflicts of interest: none to declare.
Network meta‐analyses of systemic treatments for psoriasis: a critical appraisal
There are numerous systemic medications in use for psoriasis, with additional investigational agents being studied. Head‐to‐head, randomised clinical trials are, however, rare and cannot feasibly compare all treatments. A network meta‐analysis (NMA) synthesises the available evidence to provide estimates for all pairwise comparisons. We summarise and appraise two recent NMAs assessing systemic therapies for moderate‐to‐severe psoriasis.
Revisiting atopic dermatitis and cardiovascular disease
In the June 2018 issue of British Journal of Dermatology, we wrote a commentary on the potential association (or lack thereof) between atopic dermatitis (AD) and cardiovascular disease. Our commentary, which was in response to a meta‐analysis of observational studies, noted that within the evidence to that point, there did not appear to be a consistent causal link. However, we did maintain some skepticism given the flaws in many of the studies included in that meta‐analysis.
Atopic dermatitis and cardiovascular disease: have we seen enough to refute a causal link?
Forgot your password? Enter your email address below. If your address has been previously registered, you will receive an email with instructions on how to reset your password. If you don't receive an email, you should register as a new user Please check your email for your password reset instructions.
Optimizing case reports and case series: guidance on how to improve quality
Case reports and case series remain an important part of journals and are often first to document medical breakthroughs. This article reviews their characteristics, aims and limitations. It provides information on how to increase the validity of the bedside decision‐making process that these studies report, using tools such as validated outcomes and split‐body or n‐of‐1 trials.
Is new better than tried and tested? Topical atopic dermatitis treatment in context
Forgot your password? Enter your email address below. If your address has been previously registered, you will receive an email with instructions on how to reset your password. If you don't receive an email, you should register as a new user Please check your email for your password reset instructions.
Optimizing case reports and case series: guidance on how to improve quality
Case reports and case series remain an important part of journals and are often first to document medical breakthroughs. This article reviews their characteristics, aims and limitations. It provides information on how to increase the validity of the bedside decision-making process that these studies report, using tools such as validated outcomes and split body or n-of-1 trials.
Introducing the new Evidence-Based Dermatology section
Next article in issue: Systematic reviews: let's keep them trustworthy Next article in issue: Systematic reviews: let's keep them trustworthy
Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement
Guidelines discourage the use of systemic corticosteroids for atopic dermatitis but their use remains widespread. To reach consensus among an international group of atopic dermatitis experts on the use of systemic corticosteroids for atopic dermatitis. A survey consisting of statements accompanied by visual analog scales ranging from “strongly disagree” to “neutral” to “strongly agree” was distributed to the International Eczema Council (IEC).
The global state of psoriasis disease epidemiology: a workshop report
The International Psoriasis Council, a global nonprofit organization dedicated to innovation across the full spectrum of psoriasis, led a symposium to discuss the current state of psoriasis epidemiology and to introduce the vision and development of a Global Psoriasis Atlas. The symposium was held on 9 September 2015 at the 45th annual meeting of the European Society for Dermatological Research, Rotterdam, the Netherlands.
The treatment of vulval lichen sclerosus in prepubertal girls: a critically appraised topic
SummaryLichen sclerosus is one of the dermatoses that specifically affects the anogenital skin. It has peaks of incidence in prepubertal girls and postmenopausal women. The objective of this critical appraisal was to review systematically the evidence for efficacy and safety of different treatments. There are no randomized controlled studies of treatment in prepubertal girls and most studies are small case series or case reports. There is little focus on quality of life.
Measurement properties of quality-of-life measurement instruments for infants, children and adolescents with eczema: a systematic review
Quality of life (QoL) is one of the core outcome domains identified by the Harmonising Outcome Measures for Eczema (HOME) initiative to be assessed in every eczema trial. There is uncertainty about the most appropriate QoL instrument to measure this domain in infants, children and adolescents. To systematically evaluate the measurement properties of existing measurement instruments developed and/or validated for the measurement of QoL in infants, children and adolescents with eczema.
Treatment of moderate-to-severe atopic eczema in adults within the UK: results of a national survey of dermatologists
We wanted to learn about the i) treatment approaches used for this disease in the UK; ii) factors that influence treatment decisions; and iii) perceived gaps in evidence on treatment safety and efficacy and priorities for future trials. 61 respondents from at least 35 centres reported on management of moderate-to-severe atopic eczema in adults, outwith the context of an acute flare.
Predictive phenotyping of inherited ichthyosis by next-generation DNA sequencing
Previous article in Early View: A systematic review of patient-reported outcomes in patients with cutaneous lupus erythematosus Previous article in Early View: A systematic review of patient-reported outcomes in patients with cutaneous lupus erythematosus Next article in Early View: Pulmonary function tests, interstitial lung disease and lung function decline in outpatients with classic and clinically amyopathic dermatomyositis Next article in Early View: Pulmonary function tests,...
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with C.
Contact C., search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack